Intel (INTC) Q2 2026 (USD): Adj. EPS 0.38 (exp. 0.21), Revenue 16.1bln (exp. 14.42bln)
Newsquawk Staff ·
Intel (INTC) Q2 2026 (USD): Adj. EPS 0.38 (exp. 0.21), Revenue 16.1bln (exp. 14.42bln)
What it means
A beat on both lines of this size is a materially better print than consensus, and with a name like Intel the read-through has historically hinged less on the quarter itself than on what drives it: beats built on cost discipline and one-offs have tended to fade faster than beats built on data centre or foundry momentum, which carry weight with the peer set and the broader semis complex. The pattern with this stock through its turnaround episodes is that headline beats are routinely interrogated on the call for margin quality, segment mix, and capex trajectory before the after-hours move is trusted. Guidance is the usual arbiter: prior quarters where the print beat but the outlook disappointed have seen initial strength given back, and the reverse holds as well. Worth noting the distinction between the EPS beat and the revenue beat here, since the revenue gap is the larger surprise and revenue surprises in semis have tended to be the more durable signal than bottom-line beats flattered by opex control. The follow-ons are the call commentary on foundry losses and AI-related demand, gross margin guidance, and any read-across to the equipment and merchant silicon names.
- Instacart (CART) is reportedly exploring a sale, The Information reports; held talks with DoorDash (DASH) and Uber (UBER)
- US FDA approves subcutaneous induction regimen for AbbVie’s (ABBV) Skyrizi for adults with moderately to severely active Crohn’s disease
- Kimi K3.1 Pro AI model builds GTA VI-style (TTWO) playable game demo in just 10 hours for USD 52, developer claims on X; showcases AI’s ability to generate video game experiences - UNCONFIRMED
- OpenAI expects future AI models to be capable of identifying and exploiting vulnerabilities that are currently unknown, according to a blog post
- American Express (AXP) Q3 2026 (USD): EPS 5.42 (exp. 4.50), Revenue 20.1bln (exp. 20.1bln)
Related headlines
- Texas Attorney General Ken Paxton sues OpenAI and CEO Sam Altman for lying to users and harming Texans11 hours ago
- Daily US Earnings Estimates: 26th October 2026: VZ, WELL12 hours ago
- Moonshot AI unveils 2.8tln-parameter Kimi K3.1 Pro model; says it beats Opus 5.5 and GPT-6 Astra on long-horizon coding tasks and scores top marks on SWE Marathon and agent benchmarks; pledges open weights for the 3tln-class model by November 4th12 hours ago
- The Trump administration plans to introduce voluntary “US Caught Seafood” labels to help consumers identify seafood origins, according to CBS13 hours ago
- Bristol Myers Squibb (BMY) spokesperson says the company has identified the cause of an earlier Car-T safety signal; will look to resume the paused trials in 202713 hours ago
- OpenAI reveals plans for an in-house exabyte-scale storage system13 hours ago
- Republican Senator Blackburn has raised concerns about Meta’s (META) plans to update its commercial terms, warning that the changes could “exploit American creators and businesses,” according to a letter13 hours ago
- Upside in Penguin Solutions (PEGN) attributed to M&A chatter - UNCONFIRMED 13 hours ago
- CrowdStrike (CRWD) CEO says in the coming months we will see a lot of breaches from the PHP vulnerability14 hours ago
- US President Trump says Elon Musk will not do anything wrong regarding access to Starlink (SPCX) in Ukraine14 hours ago
- CNBC speculates that Verizon (VZ) would most likely be involved in the context of a partnership with SpaceX (SPCX)14 hours ago
- Ukraine President Zelensky says the Tesla (TSLA)/SpaceX (SPCX) Starlink and Starshield service remains slowed15 hours ago
- US EQUITY OPEN: Breadth poor at the open: Energy leads gains on oil rally, Tech sees slight bounce15 hours ago
- Meta (META) says it will extend the implementation date of updated commercial terms to November 20th (prev. October 30th); extension will allow it to explain the changes to partners and stakeholders16 hours ago
- Abbott (ABT) presents new ESMO data showing 30% absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer16 hours ago